Chemotherapy + IRE for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of chemotherapy and IRE safe for treating pancreatic cancer?
FOLFIRINOX, a chemotherapy regimen used for pancreatic cancer, has been shown to have different safety profiles compared to other treatments like gemcitabine. It can cause more severe side effects such as vomiting, diarrhea, and neutropenia (low white blood cell count), so careful monitoring is important.12345
How does the treatment FOLFIRINOX + Gemcitabine differ from other treatments for pancreatic cancer?
What data supports the effectiveness of the treatment FOLFIRINOX for pancreatic cancer?
Research shows that FOLFIRINOX, a combination of chemotherapy drugs, leads to longer overall survival in patients with metastatic pancreatic cancer compared to gemcitabine, another chemotherapy drug. In a clinical trial, patients treated with FOLFIRINOX lived on average 11.1 months compared to 6.8 months for those treated with gemcitabine.1261011
Who Is on the Research Team?
Robert Martin, MD, PhD
Principal Investigator
University of Louisville
Are You a Good Fit for This Trial?
This trial is for adults over 18 with stage III pancreatic cancer. Participants must have a measurable tumor, normal liver function (AST/ALT levels within three times the upper limit), and a stable post-surgery condition as confirmed by their surgeon. They should not be in another cancer treatment trial, pregnant or breastfeeding, have certain implants near the lesion, or recent heart attacks.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either FOLFIRINOX or gemcitabine as peri-ablation treatment in combination with irreversible electroporation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- FOLFIRINOX
- Gemcitabine
- Irreversible Electroporation (IRE)
FOLFIRINOX is already approved in European Union, United States for the following indications:
- Advanced pancreatic cancer
- Metastatic pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Louisville
Lead Sponsor